Burning Rock Biotech (BNR)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from BNR's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Burning Rock Biotech's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $508M | $563M | $537M | $516M | $540M |
| Net income | -$797M | -$971M | -$654M | -$347M | -$55M |
| Free cash flow | -$682M | -$519M | -$264M | -$98M | -$34M |
| EPS (diluted) | $0.00 | — | — | — | — |
| Operating margin | -156.9% | -174.1% | -124.5% | -69.3% | -10.2% |
Where the revenue comes from
Revenue by segments, fiscal 2024. Every breakdown, year by year.
Superinvestors who own BNR
From each investor's latest 13F filing (what a 13F shows).
Insider buying
Open-market purchases by Burning Rock Biotech's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Mar 31, 2026 | Yusheng Han Director |
314,870 | $17.36 | $5M |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when BNR trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are Burning Rock Biotech insiders buying the stock?
1 open-market insider purchase of BNR in the last 12 months, from SEC Form 4 filings.
Companies like Burning Rock Biotech
All Healthcare stocks · Diagnostics & Research stocks · Stock lists
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.